Literature DB >> 11200840

A two-step schedule for the treatment of actinomycotic mycetomas.

M Ramam1, T Garg, P D'Souza, K K Verma, B K Khaitan, M K Singh, U Banerjee.   

Abstract

Actinomycotic mycetomas usually respond slowly to treatment with antibiotics. In an attempt to hasten clinical resolution, we used a 2-step regimen consisting of an intensive phase of therapy with penicillin, gentamycin and co-trimoxazole for 5-7 weeks, followed by maintenance therapy with amoxicillin and co-trimoxazole. Seven patients were treated, all of whom showed significant reduction in discharge and swelling after the intensive phase. Maintenance therapy was continued for 2-5 months after the lesions became completely inactive. Five patients completed maintenance therapy, which was given for 6-16 months (mean 10.7 months), and remained free of disease during a mean post-treatment follow-up period of 6.4 months. The other 2 patients also responded satisfactorily and continue to receive maintenance therapy. Side-effects necessitating a modification of the treatment schedule occurred in 2 patients but reversed on discontinuation of the drugs responsible. This treatment schedule produces a rapid clinical response during the initial, intensive phase and promotes compliance with the longer maintenance phase of treatment necessary to achieve a complete cure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11200840     DOI: 10.1080/000155500459367

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  6 in total

1.  Mycetoma clinically masquerading as squamous cell carcinoma: case report and literature review.

Authors:  Saira B Momin; Blakely S Richardson; Michael G Bryan; James Q Del Rosso; Narciss Mobini
Journal:  J Clin Aesthet Dermatol       Date:  2009-02

2.  Molecular diagnosis of Actinomadura madurae infection by 16S rRNA deep sequencing.

Authors:  Stephen J Salipante; Dhruba J Sengupta; Daniel R Hoogestraat; Lisa A Cummings; Bronwyn H Bryant; Catherine Natividad; Stephanie Thielges; Peter W Monsaas; Mimosa Chau; Lindley A Barbee; Christopher Rosenthal; Brad T Cookson; Noah G Hoffman
Journal:  J Clin Microbiol       Date:  2013-10-09       Impact factor: 5.948

3.  Linezolid: A novel treatment option for the treatment of a non-responsive case of actinomycotic mycetoma.

Authors:  Suman Patra; Gridharan Senthilnathan; M Ramam; Sudheer Arava; Neetu Bhari
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

4.  The case for case reports.

Authors:  Ashwin Rao; M Ramam
Journal:  Indian Dermatol Online J       Date:  2014-10

Review 5.  Mycetoma: An Update.

Authors:  Vineet Relhan; Khushbu Mahajan; Pooja Agarwal; Vijay Kumar Garg
Journal:  Indian J Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.494

6.  Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.

Authors:  Wilson Lim; Kimberly Eadie; Mickey Konings; Bart Rijnders; Ahmed H Fahal; Jason D Oliver; Mike Birch; Annelies Verbon; Wendy van de Sande
Journal:  J Antimicrob Chemother       Date:  2020-04-01       Impact factor: 5.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.